What is Leerink Partnrs’ Estimate for CLDX Q1 Earnings?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Celldex Therapeutics in a report issued on Thursday, February 13th. Leerink Partnrs analyst T. Smith forecasts that the biopharmaceutical company will post earnings of ($0.65) per share for the quarter. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share. Leerink Partnrs also issued estimates for Celldex Therapeutics’ Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.90) EPS and Q4 2025 earnings at ($0.94) EPS.

Several other research firms have also recently issued reports on CLDX. Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, January 29th. UBS Group started coverage on Celldex Therapeutics in a research note on Thursday. They issued a “buy” rating and a $44.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research note on Thursday, December 19th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.22.

Celldex Therapeutics Stock Up 3.6 %

Shares of NASDAQ CLDX opened at $23.06 on Friday. The firm has a market cap of $1.53 billion, a price-to-earnings ratio of -8.97 and a beta of 1.60. The company’s 50-day simple moving average is $24.85 and its 200-day simple moving average is $30.03. Celldex Therapeutics has a 52-week low of $20.91 and a 52-week high of $53.18.

Institutional Trading of Celldex Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. MetLife Investment Management LLC lifted its holdings in Celldex Therapeutics by 6.1% in the fourth quarter. MetLife Investment Management LLC now owns 39,620 shares of the biopharmaceutical company’s stock valued at $1,001,000 after acquiring an additional 2,288 shares during the last quarter. Natixis purchased a new stake in Celldex Therapeutics in the fourth quarter valued at $399,000. Jump Financial LLC acquired a new position in shares of Celldex Therapeutics in the 4th quarter valued at $417,000. Guggenheim Capital LLC purchased a new position in shares of Celldex Therapeutics during the 4th quarter worth $601,000. Finally, Barclays PLC grew its holdings in shares of Celldex Therapeutics by 9.6% during the 4th quarter. Barclays PLC now owns 142,914 shares of the biopharmaceutical company’s stock worth $3,611,000 after purchasing an additional 12,533 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.